(Q43199537)

15 November 2017

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia (English)

1 reference

15 November 2017

6

1 reference

15 November 2017

10

Quinten Waisfisz

1 reference

15 November 2017

Corine J Hess

1

1 reference

15 November 2017

Nicole Feller

2

1 reference

15 November 2017

Fedor Denkers

3

1 reference

15 November 2017

Angèle Kelder

4

1 reference

15 November 2017

Pauline A Merle

5

1 reference

15 November 2017

Amy Harlow

7

1 reference

15 November 2017

Johannes Berkhof

8

1 reference

15 November 2017

Gert J Ossenkoppele

9

1 reference

15 November 2017

Gerrit J Schuurhuis

11

1 reference

15 November 2017

27 November 2008

1 reference

15 November 2017

1 reference

15 November 2017

94

1 reference

15 November 2017

1

1 reference

15 November 2017

46-53

1 reference

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

15 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2625416

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

15 August 2018

1 reference

12 December 2020

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

12 December 2020

Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia

1 reference

12 December 2020

High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis

1 reference

12 December 2020

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

12 December 2020

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy

1 reference

12 December 2020

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

12 December 2020

Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

Identifiers

DOI

10.3324/HAEMATOL.13110

1 reference

15 November 2017

1 reference

15 November 2017

PubMed publication ID

19042917

1 reference